請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71909
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李建國(Chien-Kuo Lee) | |
dc.contributor.author | Ming-Hsun Tsai | en |
dc.contributor.author | 蔡明勳 | zh_TW |
dc.date.accessioned | 2021-06-17T06:14:33Z | - |
dc.date.available | 2023-03-05 | |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-09-17 | |
dc.identifier.citation | Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol (2008) 8(12):911-22. doi: 10.1038/nri2436. PubMed PMID: 18989317.
2. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5(5):375-86. doi: 10.1038/nri1604. PubMed PMID: 15864272. 3. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 95(26):15623-8. PubMed PMID: 9861020; PubMed Central PMCID: PMCPMC28094. 4. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 32:513-45. doi: 10.1146/annurev-immunol-032713-120231. PubMed PMID: 24555472; PubMed Central PMCID: PMCPMC4313732. 5. Rocha BC, Marques PE, Leoratti FMS, Junqueira C, Pereira DB, Antonelli L, et al. Type I Interferon Transcriptional Signature in Neutrophils and Low-Density Granulocytes Are Associated with Tissue Damage in Malaria. Cell Rep (2015) 13(12):2829-41. doi: 10.1016/j.celrep.2015.11.055. PubMed PMID: 26711347; PubMed Central PMCID: PMCPMC4698035. 6. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun (2014) 5:3864. doi: 10.1038/ncomms4864. PubMed PMID: 24844667; PubMed Central PMCID: PMCPMC4033792. 7. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science (1993) 260(5116):1942-6. PubMed PMID: 8100367. 8. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 294(5546):1540-3. doi: 10.1126/science.1064890. PubMed PMID: 11711679. 9. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 197(6):777-88. doi: 10.1084/jem.20021996. PubMed PMID: 12642605; PubMed Central PMCID: PMCPMC2193854. 10. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis (2016) 75(11):1909-16. doi: 10.1136/annrheumdis-2015-208562. PubMed PMID: 27009916; PubMed Central PMCID: PMCPMC5099191. 11. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol (2005) 202(2):323-35. doi: 10.1002/jcp.20137. PubMed PMID: 15389589. 12. Levy DE, Lee CK. What does Stat3 do? J Clin Invest (2002) 109(9):1143-8. doi: 10.1172/JCI15650. PubMed PMID: 11994402; PubMed Central PMCID: PMCPMC150972. 13. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci (2009) 1171:59-76. doi: 10.1111/j.1749-6632.2009.04911.x. PubMed PMID: 19723038; PubMed Central PMCID: PMCPMC3141289. 14. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol (2007) 178(5):2623-9. PubMed PMID: 17312100. 15. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr., Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell (1998) 93(5):827-39. PubMed PMID: 9630226. 16. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem (2007) 282(28):20059-63. doi: 10.1074/jbc.R700016200. PubMed PMID: 17502367. 17. Zhong Z, Wen Z, Darnell JE, Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 264(5155):95-8. PubMed PMID: 8140422. 18. Cimica V, Chen HC, Iyer JK, Reich NC. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One (2011) 6(5):e20188. doi: 10.1371/journal.pone.0020188. PubMed PMID: 21625522; PubMed Central PMCID: PMCPMC3098288. 19. Milocco LH, Haslam JA, Rosen J, Seidel HM. Design of conditionally active STATs: insights into STAT activation and gene regulatory function. Mol Cell Biol (1999) 19(4):2913-20. PubMed PMID: 10082558; PubMed Central PMCID: PMCPMC84085. 20. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A (2005) 102(23):8150-5. doi: 10.1073/pnas.0501643102. PubMed PMID: 15919823; PubMed Central PMCID: PMCPMC1149424. 21. Zhao Y, Zeng C, Tarasova NI, Chasovskikh S, Dritschilo A, Timofeeva OA. A new role for STAT3 as a regulator of chromatin topology. Transcription (2013) 4(5):227-31. PubMed PMID: 24406340. 22. Hu T, Yeh JE, Pinello L, Jacob J, Chakravarthy S, Yuan GC, et al. Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. Mol Cell Biol (2015) 35(19):3284-300. doi: 10.1128/MCB.00060-15. PubMed PMID: 26169829; PubMed Central PMCID: PMCPMC4561728. 23. Horvath CM, Wen Z, Darnell JE, Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev (1995) 9(8):984-94. PubMed PMID: 7774815. 24. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 100(16):9342-7. doi: 10.1073/pnas.1633516100. PubMed PMID: 12867595; PubMed Central PMCID: PMCPMC170920. 25. Icardi L, Mori R, Gesellchen V, Eyckerman S, De Cauwer L, Verhelst J, et al. The Sin3a repressor complex is a master regulator of STAT transcriptional activity. Proc Natl Acad Sci U S A (2012) 109(30):12058-63. doi: 10.1073/pnas.1206458109. PubMed PMID: 22783022; PubMed Central PMCID: PMCPMC3409767. 26. Zhang T, Kee WH, Seow KT, Fung W, Cao X. The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol Cell Biol (2000) 20(19):7132-9. PubMed PMID: 10982829; PubMed Central PMCID: PMCPMC86266. 27. Ma J, Zhang T, Novotny-Diermayr V, Tan AL, Cao X. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem (2003) 278(31):29252-60. doi: 10.1074/jbc.M304196200. PubMed PMID: 12746441. 28. Sato N, Tsuruma R, Imoto S, Sekine Y, Muromoto R, Sugiyama K, et al. Nuclear retention of STAT3 through the coiled-coil domain regulates its activity. Biochem Biophys Res Commun (2005) 336(2):617-24. doi: 10.1016/j.bbrc.2005.08.145. PubMed PMID: 16140268. 29. Collum RG, Brutsaert S, Lee G, Schindler C. A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc Natl Acad Sci U S A (2000) 97(18):10120-5. doi: 10.1073/pnas.170192197. PubMed PMID: 10954736; PubMed Central PMCID: PMCPMC27739. 30. Ma J, Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal (2006) 18(8):1117-26. doi: 10.1016/j.cellsig.2005.06.016. PubMed PMID: 16298512. 31. Vogt M, Domoszlai T, Kleshchanok D, Lehmann S, Schmitt A, Poli V, et al. The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. J Cell Sci (2011) 124(Pt 6):900-9. doi: 10.1242/jcs.072520. PubMed PMID: 21325026. 32. Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem (2008) 283(45):30725-34. doi: 10.1074/jbc.M805941200. PubMed PMID: 18782771; PubMed Central PMCID: PMCPMC2576556. 33. Ray S, Lee C, Hou T, Boldogh I, Brasier AR. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res (2008) 36(13):4510-20. doi: 10.1093/nar/gkn419. PubMed PMID: 18611949; PubMed Central PMCID: PMCPMC2490754. 34. Hossain DM, Panda AK, Manna A, Mohanty S, Bhattacharjee P, Bhattacharyya S, et al. FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity (2013) 39(6):1057-69. doi: 10.1016/j.immuni.2013.11.005. PubMed PMID: 24315995. 35. Tanaka T, Yamamoto Y, Muromoto R, Ikeda O, Sekine Y, Grusby MJ, et al. PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3. Sci Signal (2011) 4(202):ra85. doi: 10.1126/scisignal.2001637. PubMed PMID: 22155789. 36. Tsai MH, Lee CK. STAT3 Cooperates With Phospholipid Scramblase 2 to Suppress Type I Interferon Response. Front Immunol (2018) 9:1886. doi: 10.3389/fimmu.2018.01886. PubMed PMID: 30158934; PubMed Central PMCID: PMCPMC6104169. 37. Velichko S, Wagner TC, Turkson J, Jove R, Croze E. STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. Activation of multiple STATS proceeds through the redundant usage of two tyrosine residues. J Biol Chem (2002) 277(38):35635-41. doi: 10.1074/jbc.M204578200. PubMed PMID: 12105218. 38. Lee C, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity (2002) 17(1):63. 39. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 174(2):609-13. PubMed PMID: 15634877. 40. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT (2012) 1(2):65-72. doi: 10.4161/jkst.20045. PubMed PMID: 24058752; PubMed Central PMCID: PMCPMC3670295. 41. Wan CK, Andraski AB, Spolski R, Li P, Kazemian M, Oh J, et al. Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. Proc Natl Acad Sci U S A (2015) 112(30):9394-9. doi: 10.1073/pnas.1511711112. PubMed PMID: 26170288; PubMed Central PMCID: PMCPMC4522759. 42. Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci U S A (1998) 95(10):5568-72. PubMed PMID: 9576923; PubMed Central PMCID: PMCPMC20418. 43. Gimeno R, Lee CK, Schindler C, Levy DE. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol (2005) 25(13):5456-65. doi: 10.1128/MCB.25.13.5456-5465.2005. PubMed PMID: 15964802; PubMed Central PMCID: PMCPMC1156979. 44. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem (2006) 281(20):14111-8. doi: 10.1074/jbc.M511797200. PubMed PMID: 16571725. 45. Wang WB, Levy DE, Lee CK. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol (2011) 187(5):2578-85. doi: 10.4049/jimmunol.1004128. PubMed PMID: 21810606. 46. Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity (2014) 40(3):367-77. doi: 10.1016/j.immuni.2014.02.005. PubMed PMID: 24631156; PubMed Central PMCID: PMCPMC3992517. 47. Lu L, Zhu F, Zhang M, Li Y, Drennan AC, Kimpara S, et al. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2018) 115(3):E498-E505. doi: 10.1073/pnas.1715118115. PubMed PMID: 29295936; PubMed Central PMCID: PMCPMC5776985. 48. Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, et al. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology (2013) 58(4):1225-35. doi: 10.1002/hep.26404. PubMed PMID: 23519785. 49. Xiong Y, Zhang C, Yuan J, Zhu Y, Tan Z, Kuang X, et al. Hepatitis C virus represses the cellular antiviral response by upregulating the expression of signal transducer and activator of transcription 3 through sponging microRNA122. Mol Med Rep (2015) 11(3):1733-7. doi: 10.3892/mmr.2014.2897. PubMed PMID: 25377467; PubMed Central PMCID: PMCPMC4270330. 50. Li X, Leung S, Qureshi S, Darnell JE, Jr., Stark GR. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem (1996) 271(10):5790-4. PubMed PMID: 8621447. 51. Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, et al. The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget (2016) 7(32):51096-106. doi: 10.18632/oncotarget.9315. PubMed PMID: 27191495; PubMed Central PMCID: PMCPMC5239461. 52. Thyrell L, Arulampalam V, Hjortsberg L, Farnebo M, Grander D, Pokrovskaja Tamm K. Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp Cell Res (2007) 313(19):4015-24. doi: 10.1016/j.yexcr.2007.08.007. PubMed PMID: 17880940. 53. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature (1996) 383(6598):344-7. doi: 10.1038/383344a0. PubMed PMID: 8848048. 54. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci U S A (2003) 100(25):14742-7. doi: 10.1073/pnas.2433987100. PubMed PMID: 14645718; PubMed Central PMCID: PMCPMC299790. 55. Icardi L, Lievens S, Mori R, Piessevaux J, De Cauwer L, De Bosscher K, et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J (2012) 26(1):240-9. doi: 10.1096/fj.11-191122. PubMed PMID: 21957129. 56. Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia (2012) 26(6):1356-64. doi: 10.1038/leu.2011.340. PubMed PMID: 22116549; PubMed Central PMCID: PMCPMC3625618. 57. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell (2007) 131(1):93-105. doi: 10.1016/j.cell.2007.07.034. PubMed PMID: 17923090. 58. Ray S, Boldogh I, Brasier AR. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology (2005) 129(5):1616-32. doi: 10.1053/j.gastro.2005.07.055. PubMed PMID: 16285960. 59. Dasgupta M, Unal H, Willard B, Yang J, Karnik SS, Stark GR. Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3. J Biol Chem (2014) 289(44):30763-71. doi: 10.1074/jbc.M114.603894. PubMed PMID: 25217633; PubMed Central PMCID: PMCPMC4215253. 60. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 109(20):7765-9. doi: 10.1073/pnas.1205132109. PubMed PMID: 22547799; PubMed Central PMCID: PMCPMC3356652. 61. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol (2009) 11(4):492-500. doi: 10.1038/ncb1857. PubMed PMID: 19295512; PubMed Central PMCID: PMCPMC2790597. 62. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem (2005) 280(12):11528-34. doi: 10.1074/jbc.M413930200. PubMed PMID: 15649887. 63. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol (2004) 22:503-29. doi: 10.1146/annurev.immunol.22.091003.090312. PubMed PMID: 15032587. 64. Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol (2008) 181(5):3167-76. PubMed PMID: 18713987; PubMed Central PMCID: PMCPMC2836124. 65. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood (2002) 100(8):2926-31. doi: 10.1182/blood-2002-01-0073. PubMed PMID: 12351404. 66. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem (1998) 273(52):35056-62. PubMed PMID: 9857039. 67. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4(6):540-5. doi: 10.1038/ni931. PubMed PMID: 12754505. 68. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest (2002) 110(10):1503-13. doi: 10.1172/JCI15841. PubMed PMID: 12438448; PubMed Central PMCID: PMCPMC151811. 69. Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, Goumans MJ, et al. IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol (2010) 299(2):C354-62. doi: 10.1152/ajpcell.00513.2009. PubMed PMID: 20484656. 70. Yu T, Zuo Y, Cai R, Huang X, Wu S, Zhang C, et al. SENP1 regulates IFN-gamma-STAT1 signaling through STAT3-SOCS3 negative feedback loop. J Mol Cell Biol (2017) 9(2):144-53. doi: 10.1093/jmcb/mjw042. PubMed PMID: 27702761. 71. Carbone CJ, Zheng H, Bhattacharya S, Lewis JR, Reiter AM, Henthorn P, et al. Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies. Proc Natl Acad Sci U S A (2012) 109(47):19226-31. doi: 10.1073/pnas.1211491109. PubMed PMID: 23129613; PubMed Central PMCID: PMCPMC3511142. 72. Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics (2013) 12(6):489-98. doi: 10.1093/bfgp/elt028. PubMed PMID: 23943603; PubMed Central PMCID: PMCPMC3838198. 73. Forster SC, Tate MD, Hertzog PJ. MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. Front Immunol (2015) 6:334. doi: 10.3389/fimmu.2015.00334. PubMed PMID: 26217335; PubMed Central PMCID: PMCPMC4495342. 74. Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res (2014) 74(9):2591-603. doi: 10.1158/0008-5472.CAN-13-1606. PubMed PMID: 24607843. 75. Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFkappaB and STAT3 in colorectal cancer cells. Gastroenterology (2014) 147(4):847-59 e11. doi: 10.1053/j.gastro.2014.06.006. PubMed PMID: 24931456; PubMed Central PMCID: PMCPMC4839969. 76. Sehgal M, Zeremski M, Talal AH, Ginwala R, Elrod E, Grakoui A, et al. IFN-alpha-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. J Interferon Cytokine Res (2015) 35(9):698-709. doi: 10.1089/jir.2014.0211. PubMed PMID: 26090579; PubMed Central PMCID: PMCPMC4560851. 77. Du H, Cui S, Li Y, Yang G, Wang P, Fikrig E, et al. MiR-221 negatively regulates innate anti-viral response. PLoS One (2018) 13(8):e0200385. doi: 10.1371/journal.pone.0200385. PubMed PMID: 30089112; PubMed Central PMCID: PMCPMC6082502. 78. Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P, et al. Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol (2010) 36(6):1503-12. PubMed PMID: 20428775. 79. Basse F, Stout JG, Sims PJ, Wiedmer T. Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid. J Biol Chem (1996) 271(29):17205-10. PubMed PMID: 8663431. 80. Zhou Q, Zhao J, Stout JG, Luhm RA, Wiedmer T, Sims PJ. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem (1997) 272(29):18240-4. PubMed PMID: 9218461. 81. Sahu SK, Gummadi SN, Manoj N, Aradhyam GK. Phospholipid scramblases: an overview. Arch Biochem Biophys (2007) 462(1):103-14. doi: 10.1016/j.abb.2007.04.002. PubMed PMID: 17481571. 82. Iiri T, Backlund PS, Jr., Jones TL, Wedegaertner PB, Bourne HR. Reciprocal regulation of Gs alpha by palmitate and the beta gamma subunit. Proc Natl Acad Sci U S A (1996) 93(25):14592-7. PubMed PMID: 8962097; PubMed Central PMCID: PMCPMC26178. 83. Blanc M, David F, Abrami L, Migliozzi D, Armand F, Burgi J, et al. SwissPalm: Protein Palmitoylation database. F1000Res (2015) 4:261. doi: 10.12688/f1000research.6464.1. PubMed PMID: 26339475; PubMed Central PMCID: PMCPMC4544385. 84. Chen MH, Ben-Efraim I, Mitrousis G, Walker-Kopp N, Sims PJ, Cingolani G. Phospholipid scramblase 1 contains a nonclassical nuclear localization signal with unique binding site in importin alpha. J Biol Chem (2005) 280(11):10599-606. doi: 10.1074/jbc.M413194200. PubMed PMID: 15611084. 85. Lott K, Bhardwaj A, Sims PJ, Cingolani G. A minimal nuclear localization signal (NLS) in human phospholipid scramblase 4 that binds only the minor NLS-binding site of importin alpha1. J Biol Chem (2011) 286(32):28160-9. doi: 10.1074/jbc.M111.228007. PubMed PMID: 21690087; PubMed Central PMCID: PMCPMC3151061. 86. Inuzuka T, Inokawa A, Chen C, Kizu K, Narita H, Shibata H, et al. ALG-2-interacting Tubby-like protein superfamily member PLSCR3 is secreted by an exosomal pathway and taken up by recipient cultured cells. Biosci Rep (2013) 33(2):e00026. doi: 10.1042/BSR20120123. PubMed PMID: 23350699; PubMed Central PMCID: PMCPMC3590573. 87. Yu A, McMaster CR, Byers DM, Ridgway ND, Cook HW. Stimulation of phosphatidylserine biosynthesis and facilitation of UV-induced apoptosis in Chinese hamster ovary cells overexpressing phospholipid scramblase 1. J Biol Chem (2003) 278(11):9706-14. doi: 10.1074/jbc.M204614200. PubMed PMID: 12509439. 88. Li Y, Rogulski K, Zhou Q, Sims PJ, Prochownik EV. The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1. Mol Cell Biol (2006) 26(9):3401-13. doi: 10.1128/MCB.26.9.3401-3413.2006. PubMed PMID: 16611984; PubMed Central PMCID: PMCPMC1447419. 89. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, et al. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One (2009) 4(3):e5006. doi: 10.1371/journal.pone.0005006. PubMed PMID: 19333378; PubMed Central PMCID: PMCPMC2659420. 90. Wiedmer T, Zhao J, Nanjundan M, Sims P. Palmitoylation of phospholipid scramblase 1 controls its distribution between nucleus and plasma membrane. Biochemistry (2003) 42(5):1227. 91. Zhou Q, Zhao J, Wiedmer T, Sims PJ. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood (2002) 99(11):4030-8. doi: 10.1182/blood-2001-12-0271. PubMed PMID: 12010804. 92. Talukder AH, Bao M, Kim TW, Facchinetti V, Hanabuchi S, Bover L, et al. Phospholipid scramblase 1 regulates Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Cell Res (2012) 22(7):1129-39. doi: 10.1038/cr.2012.45. PubMed PMID: 22453241; PubMed Central PMCID: PMCPMC3391020. 93. Dong B, Zhou Q, Zhao J, Zhou A, Harty RN, Bose S, et al. Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J Virol (2004) 78(17):8983-93. doi: 10.1128/JVI.78.17.8983-8993.2004. PubMed PMID: 15308695; PubMed Central PMCID: PMCPMC506946. 94. Yang J, Zhu X, Liu J, Ding X, Han M, Hu W, et al. Inhibition of Hepatitis B virus replication by phospholipid scramblase 1 in vitro and in vivo. Antiviral Res (2012) 94(1):9-17. doi: 10.1016/j.antiviral.2012.01.010. PubMed PMID: 22342889. 95. Chen SH, Hu CP, Chang CM. Hepatitis B virus replication in well differentiated mouse hepatocyte cell lines immortalized by plasmid DNA. Cancer Res (1992) 52(5):1329-35. PubMed PMID: 1737394. 96. Huang PY, Guo JH, Hwang LH. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther (2012) 20(2):298-305. doi: 10.1038/mt.2011.245. PubMed PMID: 22068428; PubMed Central PMCID: PMCPMC3277240. 97. Tai KF, Chen PJ, Chen DS, Hwang LH. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. The journal of gene medicine (2003) 5(5):386-98. Epub 2003/05/06. doi: 10.1002/jgm.376. PubMed PMID: 12731087. 98. Huang CY, Chang W. Imaging of vaccinia virus entry into HeLa cells. Methods in molecular biology (Clifton, NJ) (2012) 890:123-33. Epub 2012/06/13. doi: 10.1007/978-1-61779-876-4_7. PubMed PMID: 22688764. 99. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature biotechnology (2014) 32(4):347-55. Epub 2014/03/04. doi: 10.1038/nbt.2842. PubMed PMID: 24584096; PubMed Central PMCID: PMCPmc4022601. 100. Makarova O, Kamberov E, Margolis B. Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques (2000) 29(5):970-2. PubMed PMID: 11084856. 101. Lee CK, Bluyssen HA, Levy DE. Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity. J Biol Chem (1997) 272(35):21872-7. Epub 1997/08/29. PubMed PMID: 9268319. 102. Chen TT, Tsai MH, Kung JT, Lin KI, Decker T, Lee CK. STAT1 regulates marginal zone B cell differentiation in response to inflammation and infection with blood-borne bacteria. J Exp Med (2016) 213(13):3025-39. doi: 10.1084/jem.20151620. PubMed PMID: 27849553; PubMed Central PMCID: PMCPMC5154933. 103. Brigidi GS, Bamji SX. Detection of protein palmitoylation in cultured hippocampal neurons by immunoprecipitation and acyl-biotin exchange (ABE). J Vis Exp (2013) (72):e50031. doi: 10.3791/50031. PubMed PMID: 23438969; PubMed Central PMCID: PMCPMC3605617. 104. Kasembeli M, Lau WC, Roh SH, Eckols TK, Frydman J, Chiu W, et al. Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS biology (2014) 12(4):e1001844. Epub 2014/04/24. doi: 10.1371/journal.pbio.1001844. PubMed PMID: 24756126; PubMed Central PMCID: PMCPmc3995649. 105. Liu S, Hao X, Ouyang X, Dong X, Yang Y, Yu T, et al. Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study. Oncotarget (2016) 7(46):75468-81. Epub 2016/10/01. doi: 10.18632/oncotarget.12258. PubMed PMID: 27690342; PubMed Central PMCID: PMCPmc5342753. 106. Sass JO, Mohr V, Olbrich H, Engelke U, Horvath J, Fliegauf M, et al. Mutations in ACY1, the gene encoding aminoacylase 1, cause a novel inborn error of metabolism. American journal of human genetics (2006) 78(3):401-9. Epub 2006/02/09. doi: 10.1086/500563. PubMed PMID: 16465618; PubMed Central PMCID: PMCPMC1380284. 107. Block H, Stadtmann A, Riad D, Rossaint J, Sohlbach C, Germena G, et al. Gnb isoforms control a signaling pathway comprising Rac1, Plcbeta2, and Plcbeta3 leading to LFA-1 activation and neutrophil arrest in vivo. Blood (2016) 127(3):314-24. Epub 2015/10/16. doi: 10.1182/blood-2015-06-651034. PubMed PMID: 26468229; PubMed Central PMCID: PMCPMC4722285. 108. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 18(17):4657-68. doi: 10.1093/emboj/18.17.4657. PubMed PMID: 10469645; PubMed Central PMCID: PMCPMC1171539. 109. De Andrea M, Ritta M, Landini MM, Borgogna C, Mondini M, Kern F, et al. Keratinocyte-specific stat3 heterozygosity impairs development of skin tumors in human papillomavirus 8 transgenic mice. Cancer Res (2010) 70(20):7938-48. doi: 10.1158/0008-5472.CAN-10-1128. PubMed PMID: 20876801. 110. Fensterl V, Wetzel JL, Ramachandran S, Ogino T, Stohlman SA, Bergmann CC, et al. Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 8(5):e1002712. doi: 10.1371/journal.ppat.1002712. PubMed PMID: 22615570; PubMed Central PMCID: PMCPMC3355090. 111. Fensterl V, Wetzel JL, Sen GC. Interferon-induced protein Ifit2 protects mice from infection of the peripheral nervous system by vesicular stomatitis virus. J Virol (2014) 88(18):10303-11. doi: 10.1128/JVI.01341-14. PubMed PMID: 24991014; PubMed Central PMCID: PMCPMC4178895. 112. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol (2006) 6(8):602-12. doi: 10.1038/nri1885. PubMed PMID: 16868551. 113. Herrmann A, Sommer U, Pranada AL, Giese B, Kuster A, Haan S, et al. STAT3 is enriched in nuclear bodies. J Cell Sci (2004) 117(Pt 2):339-49. doi: 10.1242/jcs.00833. PubMed PMID: 14657276. 114. Rayala S, Francis VG, Sivagnanam U, Gummadi SN. N-terminal proline-rich domain is required for scrambling activity of human phospholipid scramblases. J Biol Chem (2014) 289(19):13206-18. doi: 10.1074/jbc.M113.522953. PubMed PMID: 24648509; PubMed Central PMCID: PMCPMC4036332. 115. Aicart-Ramos C, Valero RA, Rodriguez-Crespo I. Protein palmitoylation and subcellular trafficking. Biochim Biophys Acta (2011) 1808(12):2981-94. doi: 10.1016/j.bbamem.2011.07.009. PubMed PMID: 21819967. 116. Zou C, Ellis BM, Smith RM, Chen BB, Zhao Y, Mallampalli RK. Acyl-CoA:lysophosphatidylcholine acyltransferase I (Lpcat1) catalyzes histone protein O-palmitoylation to regulate mRNA synthesis. J Biol Chem (2011) 286(32):28019-25. doi: 10.1074/jbc.M111.253385. PubMed PMID: 21685381; PubMed Central PMCID: PMCPMC3151047. 117. Cao N, Li JK, Rao YQ, Liu H, Wu J, Li B, et al. A potential role for protein palmitoylation and zDHHC16 in DNA damage response. BMC Mol Biol (2016) 17(1):12. doi: 10.1186/s12867-016-0065-9. PubMed PMID: 27159997; PubMed Central PMCID: PMCPMC4862184. 118. Chen X, Du Z, Li X, Wang L, Wang F, Shi W, et al. Protein Palmitoylation Regulates Neural Stem Cell Differentiation by Modulation of EID1 Activity. Mol Neurobiol (2016) 53(8):5722-36. doi: 10.1007/s12035-015-9481-y. PubMed PMID: 26497028. 119. Kusano S, Eizuru Y. Interaction of the phospholipid scramblase 1 with HIV-1 Tat results in the repression of Tat-dependent transcription. Biochem Biophys Res Commun (2013) 433(4):438-44. doi: 10.1016/j.bbrc.2013.02.098. PubMed PMID: 23501106. 120. Hernandez-Hansen V, Bard JD, Tarleton CA, Wilder JA, Lowell CA, Wilson BS, et al. Increased expression of genes linked to FcepsilonRI Signaling and to cytokine and chemokine production in Lyn-deficient mast cells. J Immunol (2005) 175(12):7880-8. PubMed PMID: 16339523. 121. Amir-Moazami O, Alexia C, Charles N, Launay P, Monteiro RC, Benhamou M. Phospholipid scramblase 1 modulates a selected set of IgE receptor-mediated mast cell responses through LAT-dependent pathway. J Biol Chem (2008) 283(37):25514-23. doi: 10.1074/jbc.M705320200. PubMed PMID: 18579528. 122. Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod JML, Pisanelli G, Pham A, et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is a | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71909 | - |
dc.description.abstract | 第一型干擾素(IFN-I)是一種具有多功效的細胞激素去調節先天及適應性免疫反應。我們在先前已發現STAT3可藉其蛋白質N端去抑制第一型干擾素反應,這個作用和DNA結合能力及轉錄功能無關,我們利用酵母菌雜交法去發現PLSCR2可結合STAT3去抑制第一型干擾素的反應。PLSCR2是一個干擾素下游基因(IFN-stimulated gene) 且主要在細胞核中類似核小體的結構與STAT3結合,而大量表現PLSCR2會減弱ISRE報導基因的活性,如果STAT3和PLSCR2的一起表現會使這個現象更明顯。此外,PLSCR2的缺失會增強第一型干擾素下游基因的表現以及抗病毒活性,這個作用不是去影響STAT1和STAT2的活化及進核以及ISGF3的組合,而是藉由抑制ISGF3和啟動子結合來達成,此外,STAT3的存在會加強這個抑制的效果。另外我們也發現這抑制效果與STAT3的結合能力以及PLSCR2的棕櫚酸酯化(palmitoylation)有關。PLSCR2也可以和STAT2結合而調節ISGF3的轉錄活性,但STAT2的抑制機轉和PLSCR2棕櫚酸酯化無關,可見得STAT2跟與STAT3的作用不一樣。最後,我們產生PLSCR2基因剔除小鼠並測試其抗病毒感染的能力。PLSCR2缺陷的小鼠在腳墊注射口炎病毒(VSV)後比正常控制組的小鼠較不容易死亡。然而如果是用流感病毒(IAV)做鼻腔感染,則相反比較容易死亡,其原因可能是因為過度發炎反應所導致。的確,PLSCR2缺陷小鼠在脂多醣(LPS)所引發的全身性休克測試中也呈現出比較容易死亡的症狀,這些結果顯示PLSCR2的確在體內實驗中也具有抑制抗病毒反應及抗發炎作用。總合來看,我們的研究提出了一個新穎的STAT3-PLSCR2軸去微調第一型干擾素的反應。 | zh_TW |
dc.description.abstract | Type I interferon (IFN-I) is a pluripotent cytokine that modulates innate and adaptive immunity. We have previously shown that STAT3 suppresses IFN-I response in a manner dependent on its N-terminal domain (NTD), but independent of its DNA-binding and transactivation ability. Using the yeast two-hybrid system, we have identified phospholipid scramblase 2 (PLSCR2) as a STAT3 NTD binding partner and a suppressor of IFN-I response. PLSCR2 is an IFN-stimulated gene (ISG) and predominantly locates to and interacts with STAT3 in the nucleus, probably in the nuclear body structure. Overexpression of PLSCR2 attenuates ISRE-driven reporter activity, which is further aggravated by co-expression of STAT3. Moreover, PLSCR2 deficiency enhances IFN-I-induced gene expression and antiviral activity without affecting the activation or nuclear translocation of STAT1 and STAT2 or the assembly of ISGF3 complex. Instead, PLSCR2 impedes promoter occupancy by ISGF3, an effect further intensified by the presence of STAT3. Moreover, palmitoylation of PLSCR2 is required for its binding to STAT3 and for this suppressive activity. In addition, PLSCR2 also interacts with STAT2, which facilitates the suppressive effect on ISGF3-mediated transcriptional activity. Moreover, the suppressive effect of STAT2 and STAT3 is distinct, as the palmitoylation domain of PLSCR2 is dispensable. Finally, PLSCR2KO mice are generated and subjected to viral infections. PLSCR2KO mice are more resistant to VSV infection than WT control through footpad injection. Interestingly, the mutant mice are, otherwise, more susceptible to influenza virus infection through intranasal route, which may be due to enhanced inflammatory response. Indeed, in LPS-induced systemic shock assay, PLSCR2KO mice are more susceptible than WT control. Therefore, we also demonstrate a role of PLSCR2 in vivo in suppressing antiviral and inflammatory responses. Together, these results define the role of a novel STAT3-PLSCR2 axis in fine-tuning IFN-I response. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:14:33Z (GMT). No. of bitstreams: 1 ntu-107-D98449001-1.pdf: 12474664 bytes, checksum: 3667cf3d921e7b3df486129d0ebf3a5e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii ABSTRACT iv CONTENTS vi LIST OF FIGURES viii Chapter 1 Introduction 1 1.1 IFN-I signaling pathways 1 1.2 The structure of STAT3 3 1.3 STAT3 as a negative regulator of IFN-I signaling pathway 4 1.4 The mechanism for negative regulation of IFN-I by STAT3 - direct effects 7 1.4.1 Sequestering STAT1 from ISGF3 7 1.4.2 Regulation of IFN-I response by epigenetic modification 7 1.5 The mechanism for negative regulation of IFN-I by STAT3 - indirect effects 9 1.5.1 Induction of negative regulators 9 1.5.2 Reduction of ISGF3 components 10 1.6 Phospholipid scramblase in innate immunity 11 1.7 Research highlights 13 Chapter 2 Materials and methods 14 2.1 Yeast two-hybrid assay 14 2.2 Cell lines and viruses 15 2.3 Antibodies, cytokines, and inhibitors 16 2.4 DNA constructs 16 2.5 Animals and hydrodynamic gene transfer (HGT) 18 2.6 Quantitative real-time PCR 18 2.7 Lentivirus-mediated shRNA delivery 19 2.8 Immunoprecipitation and western blot analysis 20 2.9 Reporter activity assay 21 2.10 Immunofluorescent microscopy 22 2.11 Chromatin immunoprecipitation (ChIP) assay 23 2.12 Antiviral assay and titration of viruses 24 2.13 Electrophoretic mobility shift assay (EMSA) 25 2.14 Palmitoylation assay 26 2.15 Statistical Analysis 27 Chapter 3 Results 28 3.1 Identification of STAT3 NTD-interacting proteins using the yeast two-hybrid system 28 3.2 PLSCR2 is a IFN-inducible STAT3-interacting protein and is predominantly located to the nucleus 29 3.3 PLSCR2 suppresses IFN-I response and antiviral activity 32 3.4 PLSCR1 positively regulates IFN-I response 33 3.5 PLSCR2KO cells exhibit increased basal and IFN-induced gene expression 35 3.6 The suppressive effects of PLSCR2 are STAT3-dependent 36 3.7 Palmitoylation of PLSCR2 is required for its interaction with STAT3 and for its suppressive activities 38 3.8 PLSCR2 suppresses the recruitment of ISGF3 to promoters of ISGs 38 3.9 The suppressive effect of PLSCR2 is also STAT2-dependent 41 3.10 PLSCR2 suppresses antiviral and inflammatory responses in vivo 42 Chapter 4 Discussion 46 4.1 The interaction between STAT3 and PLSCR2 in nucleus 46 4.2 Palmitoylation of PLSCR2 47 4.3 PLSCR1 in IFN-I response 48 4.4 Mechanisms of blocking ISGF3 recruitment to DNA 49 4.5 Targeting STAT3 to strength antiviral response 50 REFERENCES 53 | |
dc.language.iso | en | |
dc.title | STAT3與PLSCR2 協同作用去負調節第一型干擾素的反應 | zh_TW |
dc.title | STAT3 cooperates with PLSCR2 to suppress type I interferon response | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 林琬琬(Wan-Wan Lin),徐立中(Li-Chung Hsu),陳念榮(Nien-Jung Chen),曾炳輝(Ping-Hui Tseng) | |
dc.subject.keyword | STAT3,PLSCR2,第一型干擾素,干擾素下游基因,棕櫚酸酯化, | zh_TW |
dc.subject.keyword | STAT3,PLSCR2,type I interferon,interferon-stimulated gene,palmitoylation, | en |
dc.relation.page | 87 | |
dc.identifier.doi | 10.6342/NTU201804119 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-09-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 12.18 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。